A Rare Genetic Mutation Leads to Cancer. The Fix May Already Be in the Drugstore.
A common dietary supplement may help overcome mutations in the Pten gene. Should patients take it?
Publication date: Available online 25 June 2019Source: Meta GeneAuthor(s): Roby Will Vencatto, Susana Ramalho, Fernando Augusto Lima Marson, Luciana Montes Rezende, Stéphanie Villa-Nova Pereira, Luciana Cardoso Bonadia, Carmen Silvia Passos Lima, Carmen Silvia BertuzzoAbstractBreast cancer (BC) is the second most prevalent type of cancer worldwide and the most common among women. Also, BC shows different subtypes and patterns of chemotherapy response. Moreover, BC recurrence pattern is not well knowledge. But, genetic variants can alter drug pharmacokinetics and pharmacodynamics with an impact in treatment outcome. ...
Publication date: Available online 24 June 2019Source: European UrologyAuthor(s): Yu Wei, Junlong Wu, Weijie Gu, Xiaojian Qin, Bo Dai, Guowen Lin, Hualei Gan, Stephen J. Freedland, Yao Zhu, Dingwei YeAbstractGenetic testing for prostate cancer (PCa) patients is in constant development. Specific genetic alterations indicate personalized managing strategies, requiring clinicians to refer appropriate patients for genetic testing. However, our understanding of genetic epidemiology of PCa is mainly based on data from Caucasian populations. In addition, there is evidence that alterations in DNA repair genes (DRGs) may be ethnic ...
ConclusionsTo our knowledge, this is the largest study to date detailing the comorbidities associated with LE and LE treatment rates within each. Our findings suggest that a sizable proportion of cancer-related LE patients do not receive appropriate treatment. Furthermore, this study highlights the role of advanced venous disease as an LE comorbidity that is frequently untreated and its associated gap in treatment.
ConclusionsSupplemental training helps radiologists improve their screening performance, despite the mainly moderate quality of the studies. There is a need for better designed studies. Future studies should focus on performance in actual screening practice and should look for methods to isolate the training effect. If test sets are used, focus should be on knowledge about correlation between performance on test sets and actual screening practice.
Condition: Metastatic Breast Cancer Interventions: Drug: Pyrotinib; Drug: Treatment of physician's choice; Drug: vinorelbine Sponsors: Sun Yat-sen University; Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Conditions: Breast Cancer Female; Dysphagia; Adjuvant Radiotherapy Intervention: Device: Hepilor Sponsor: Cynthia Aristei Completed
ConclusionEIBR results in acceptable QoL and surgical results. In patients with a prior RT, QoL is significantly lower and surgical results are significantly worse. However, high acceptance rates suggest EIBR being a justifiable option even for this group. Prospective studies and long-term follow-up are required for definitive conclusions.
ConclusionAlmost all patients with ILRR were operated. Especially patients with hormone receptor-negative recurrent breast cancer seemed to show a benefit having been treated with chemotherapy. Most patients were without recurrence after their particular therapies.
Study found low levels of alcohol (AC) health literacy and numeracy. In 205 women and 33 NHS staff, AC was identified as breast cancer (BC) risk factor by 19.5% and 48.5%, respectively.Both groups had concerns about how to talk about AC and BC risk factors in non-stigmatising way
Authors: Ding W, Li D, Zhang P, Shi L, Dai H, Li Y, Bao X, Wang Y, Zhang H, Deng L Abstract Breast cancer is a highly heterogeneous disease and numerous secreted factors may differentially contribute to a macrophage phenotype whose extensive infiltration is generally regarded as indicative of an unfavorable outcome. How different breast tumor cells and macrophage cells interplay or influence each other on the alternative splicing (AS) level have not been characterized. Here, we exploited one previous study, which investigated the interplay between macrophages and estrogen receptor‑positive (ER+) breast cancer and...